Cerebral Adrenoleukodystrophy (CALD) Market Report 2026

Cerebral Adrenoleukodystrophy (CALD) Market Overview

• Cerebral Adrenoleukodystrophy (CALD) market size has reached to $7.54 billion in 2025 • Expected to grow to $14.72 billion in 2030 at a compound annual growth rate (CAGR) of 14.2% • Growth Driver: Impact Of Incremental Healthcare Spending On Market Growth • Market Trend: Advancements In Small-Molecule Innovation For Cald Management • North America was the largest region in 2025.

What Is Covered Under Cerebral Adrenoleukodystrophy (CALD) Market?

Cerebral adrenoleukodystrophy (CALD) is a rare, progressive neurological disorder that primarily affects males and is caused by mutations in the ABCD1 gene. It is characterized by the accumulation of very long-chain fatty acids in the brain, which destroys myelin, the protective covering of nerve cells. Cerebral adrenoleukodystrophy (CALD) is a form of adrenoleukodystrophy (ALD) that involves the brain and spinal cord, causing symptoms such as cognitive decline, behavioral changes, and motor dysfunction. The main types of treatment in the cerebral adrenoleukodystrophy (CALD) are dietary management, medications and stem cell therapy. Dietary management approach involves modifying the patient's diet to manage cerebral adrenoleukodystrophy (CALD) symptoms. The various patient age groups include adults, children, infants, and teens, and several end users including healthcare facilities, patients and caregivers, and pharmaceutical companies.

What Is The Cerebral Adrenoleukodystrophy (CALD) Market Growth Forecast?

The cerebral adrenoleukodystrophy (cald) market size is expected to see rapid growth in the next few years. It will grow to $14.72 billion in 2030 at a compound annual growth rate (CAGR) of 14.2%. The growth in the forecast period can be attributed to increasing adoption of gene therapy solutions, rising investments in rare disease drug development, expansion of newborn screening initiatives, growing focus on personalized treatment approaches, increasing collaboration between research and clinical centers. Major trends in the forecast period include increasing research into gene therapy approaches, growing use of early diagnostic screening programs, expansion of stem cell transplantation treatments, rising focus on rare disease awareness, enhanced supportive care management.

What Is The Driver Of The Cerebral Adrenoleukodystrophy (CALD) Market?

The incremental healthcare spending is expected to propel the growth of the cerebral adrenoleukodystrophy (CALD) market going forward. Healthcare spending is increasing due to aging populations, chronic diseases, medical advancements, rising drug costs, and expanded health coverage. Healthcare spending supports cerebral adrenoleukodystrophy (CALD) by enabling advancements in diagnostic tools, funding innovative treatments such as gene therapy and stem cell transplantation, and improving patient access to specialized care and early intervention. For instance, in December 2024, according to the Centers for Medicare And Medicaid Services (CMS), a US-based federal agency, national health expenditures (NHE) grew by 7.5% in 2023, outpacing the gross domestic product (GDP) growth of 6.1%. Between 2023 and 2032, average national health expenditures (NHE) are projected to grow at an average annual rate of 5.6%, increasing the health spending share of domestic product (GDP) from 17.3% in 2022 to 19.7% in 2032. Therefore, incremental healthcare spending is driving the growth of the cerebral adrenoleukodystrophy (CALD) industry.

Key Players In The Global Cerebral Adrenoleukodystrophy (CALD) Market

Major companies operating in the cerebral adrenoleukodystrophy (cald) market are Bluebird Bio Inc., Minoryx Therapeutics S.L., SwanBio Therapeutics Inc., Magenta Therapeutics Inc., Novartis AG, Vertex Pharmaceuticals Inc., MedDay Pharmaceuticals SAS, SOM Biotech Inc., Autobahn Therapeutics Inc., Orpheris Inc., Sperogenix Therapeutics Inc., NeuroVia Inc., REGENXBIO Inc., Ultragenyx Pharmaceutical Inc., Taysha Gene Therapies Inc., Neurogene Inc., Applied Genetic Technologies Corporation, Oxford BioMedica plc, UniQure N.V.

Global Cerebral Adrenoleukodystrophy (CALD) Market Trends and Insights

Major companies operating in the cerebral adrenoleukodystrophy (cALD) market are increasingly focusing on developing innovative oral small-molecule therapies, such as selective PPARγ agonists, to enhance neuroprotective activity, improve central nervous system penetration, and offer safer, more convenient alternatives to invasive or less targeted treatment approaches. A PPARγ agonist (Peroxisome Proliferator-Activated Receptor gamma agonist) is a type of drug or molecule that activates the PPARγ receptor, a nuclear hormone receptor found mainly in fat cells (adipocytes), immune cells, and muscle tissue. For instance, in May 2023, Minoryx Therapeutics, a Spain-based biotech company, received FDA approval to initiate its Phase 3 CALYX trial of leriglitazone (MIN-102). Leriglitazone is a novel, orally bioavailable, brain-penetrant, and selective PPARγ agonist that targets neuroinflammation, mitochondrial dysfunction, demyelination, and axonal degeneration mechanisms that underlie cALD progression. Unlike traditional approaches such as HSCT or gene therapy, which are invasive, risky, and not feasible for many adult patients, leriglitazone offers a non-cellular, potentially safer, and more accessible treatment option. In compassionate-use studies, leriglitazone has been well tolerated and has demonstrated the ability to stabilize both clinical and radiological disease markers in adult cALD patients.

What Are Latest Mergers And Acquisitions In The Cerebral Adrenoleukodystrophy (CALD) Market?

In June 2025, Carlyle, a US-based global investmentcompany, and SK Capital Partners, a US-based private investment company focused on the specialty materials and life sciences sectors, jointly completed the acquisition of bluebird bio for an undisclosed amount. This acquisition aims to accelerate the development and commercialization of innovative cell and gene therapies by providing enhanced capital support, strategic expertise, and operational scale. bluebird bio is a US-based biotechnology company, that offers cerebral adrenoleukodystrophy.

What Defines the Cerebral Adrenoleukodystrophy (CALD) Market?

The cerebral adrenoleukodystrophy (CALD) market consists of revenues earned by entities by providing services such as genetic testing, diagnostic imaging, medical consultations, hematopoietic stem cell transplantation, patient monitoring, counseling and long-term care management for individuals affected by cerebral adrenoleukodystrophy (CALD). The market value includes the value of related goods sold by the service provider or included within the service offering. The cerebral adrenoleukodystrophy (CALD) market also includes sales of gene therapies, corticosteroids and supportive care treatments aimed at managing symptoms and slowing disease progression. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cerebral Adrenoleukodystrophy (CALD) Market Report 2026?

The cerebral adrenoleukodystrophy (cald) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cerebral adrenoleukodystrophy (cald) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.